http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EC-SP045179-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b8be6a6c990669567cc455d32b00535e |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-00 |
| filingDate | 2004-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0041588da1b55410eb7be519abc5b71d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a142c764f085415b6c9cb68d672593ae |
| publicationDate | 2004-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EC-SP045179-A |
| titleOfInvention | TIBOLONE IN THE TREATMENT OF DISORDERS ASSOCIATED WITH THE ADMINISTRATION OF DRUGS THAT PREVENT SYNTHESIS OF THE ENDOGENOUS STRATEGY |
| abstract | The present invention relates to a treatment for disorders related to estrogen deficiency in women presenting such disorders while being treated with a drug that prevents the synthesis of endogenous estrogen. Such drugs are, for example, anti-cancer drugs such as aromatase inhibitors. The invention lies in the use of tibolone that presents an unexpected beneficial action in this specific group of patients, since it does not stimulate the breasts while preventing the loss of bone mass and relieves climacteric disorders, in a group of patients in which This situation is more complicated than in any other group, due to the nature of the concomitant treatment of cancer (the lack of circulating estrogen causes a greater severity in the disorders and the lack of effect on the estrogen receptor increases the risk associated with stimulation estrogen of the breasts once estrogen type compounds are administered). |
| priorityDate | 2002-01-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419536423 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID444008 |
Total number of triples: 22.